


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Collins et al.
Serial No.: 10/783,020
Confirmation No.: 3753
Filed: February 23, 2004
For: BIFIDOBACTERIUM IN THE TREATMENT OF
INFLAMMATORY DISEASE
Examiner: Vera Afremova
Art Unit: 1651

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 6th day of June, 2006.



Nicole M. Hawes

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office action, but before the mailing date of any final action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Serial No.: 10/783,020
Conf. No.: 3753

- 3 -

Art Unit: 1651

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By: Patricia Granahan
Patricia Granahan, Reg. No. 32,227
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: A0870.70000US00
Date: June 6, 2006
xNDDx

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/783,020		ATTY. DOCKET NO.: A0870.70000US00	
				FILING DATE: February 23, 2004		CONFIRMATION NO.: 3753	
				APPLICANT: Collins et al.			
				GROUP ART UNIT: 1651		EXAMINER: Vera Afremova	
Sheet	1	of	10				

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A1	4,347,240		Mutai et al.	08-31-1982
	A2	4,435,389		Mutai et al.	03-06-1984
	A3	5,032,399		Gorbach et al.	07-16-1991
	A4	5,443,826		Borody	08-22-1995
	A5	5,711,977		Yang et al.	01-27-1998
	A6	5,834,423		Koketsu et al.	11-10-1998
	A7	5,922,375		Luchansky et al.	07-13-1999
	A8	6,025,008		Akahoshi et al.	02-15-2000
	A9	6,077,504		Cavaliere ved. Vesley et al.	06-20-2000
	A10	6,132,710		Panigraphi et al.	10-17-2000
	A11	6,368,591		Chen et al.	04-09-2002
	A12	6,645,530		Borody	11-11-2003
	A13	2005-0214272	A1	Collins et al.	09-29-2005
	A14	2006-0002908	A1	Collins et al.	01-05-2006

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	B1	EP	0 384 319	B1	VISKASE CORPORATION	04-28-1999	
	B2	EP	0 508 701	B1	QUEST INTERNATIONAL B.V.	07-10-1996	
	B3	EP	0 904 784	A1	N.V. NUTRICIA	03-31-1999	
	B4	EP	1 312 667	A1	WAKAMOTO PHARMACEUTICAL CO., LTD.	05-21-2003	
	B5	GB	1 503 094		NISSHIN FLOUR MILLING CO. LTD.	03-08-1978	
	B6	JP	9241173		WAKAMOTO PHARMACEUT CO.	09-16-1997	Y-Abstract
	B7	RU	2 091 075	C1	GNII GENETIKI I SELEKTSII PROM	09-27-1997	Y-Abstract
	B8	RU	2 109 054	C1	MOSKOVSKJJ	04-20-1998	Y-Abstract
	B9	WO	89/05849	A1	CHR. HANSEN'S LABORATORIUM	06-29-1989	
	B10	WO	90/01335	A1	THOMAS BORODY	02-22-1990	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/783,020		ATTY. DOCKET NO.: A0870.70000US00	
				FILING DATE: February 23, 2004		CONFIRMATION NO.: 3753	
				APPLICANT: Collins et al.			
				GROUP ART UNIT: 1651		EXAMINER: Vera Afremova	
Sheet	2	of	10				

	B11	WO	90/09398	A1	BIOINVENT INTERNATIONAL AB	08-23-1990	
	B12	WO	97/35596	A1	ABBOTT LABORATORIES	10-02-1997	
	B13	WO	98/00035	A1	CAVALIERE VED. VESELY	01-08-1998	
	B14	WO	98/35014	A2	FORBAIRT TRADINGS AS BIORESEARCH IRELAND	08-13-1998	
	B15	WO	99/51631	A1	KORHONEN	10-14-1999	
	B16	WO	99/62348	A1	ENTERPRISE IRELAND	12-09-1999	
	B17	WO	01/37865	A1	PROBIAL PTY LIMITED	05-31-2001	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C1	Adachi, Susumu, "Lactic Acid Bacteria and the Control of Tumours," The Lactic Acid Bacteria, 1:233-261, (1992).	
	C2	Anand et al., "Antibacterial Activity Associated with Bifidobacterium bifidum - II," Cult. Dairy Prod, pages 21-23, (1985). (Attached copy is missing 1 page)	
	C3	Arai et al., "Cytokines: Coordinators of Immune and Inflammatory Responses," Annual Rev. Biochem., 59:783-836, (1990).	
	C4	Aranda et al., "Analysis of Intestinal Lymphocytes in Mouse Colitis Mediated by Transfer of CD4 ⁺ , CD45RB ^{high} T Cells to SCID Recipients ¹ ," Jour. of Immunology, 158(7):3464-3473, (1997).	
	C5	Arihara, et al., "Salivacin 140, a novel bacteriocin from Lactobacillus salivarius subsp. salicinius T140 active against pathogenic bacteria," Letters in Applied Microbiology, 22:420-424, (1996).	
	C6	Bachwich, et al., "Tumor Necrosis Factor Stimulates Interleukin-1 and Prostaglandin E ₂ Production in Resting Macrophages," Biochemical and Biophysical Res. Comm., 136(1):94-101, (1986).	
	C7	Blum et al., "Adhesion studies for probiotics: need for validation and refinement," Trends in Food Science & Technology, 10:405-410 (1999).	
	C8	Bouhnik et al., "Effects of Bifidobacterium sp fermented milk ingested with or without inulin on colonic bifidobacteria and enzymatic activities in healthy humans," Eur. Jour. Clin. Nut., 50:269-273, (1996).	
	C9	Bouhnik et al., "Survie et effets chez l'homme des bactéries ingérées dans less laits fermentés," LAIT, 73:241-247, (1993).	Y-Abstract
	C10	Brandtzaeg et al., "Immunopathology of human inflammatory bowel disease," Springer Semin Immunopath, 18:555-589, (1997).	
	C11	Brink et al., "Antimicrobial activity of lactobacilli: preliminary characteristization and optimization of production of acidocin B a novel bacteriocin produced by Lactobacillus acidophilus M," Jour. of Applied Bacteriology, 77:140-148, (1994).	
	C12	Brzuszczyk et al., "Cyclic AMP-dependent anion secretion in human small and large intestine," Jour. of Gastroenterology and Hepatology, 11:804-810, (1996).	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/783,020		ATTY. DOCKET NO.: A0870.70000US00	
				FILING DATE: February 23, 2004		CONFIRMATION NO.: 3753	
				APPLICANT: Collins et al.			
				GROUP ART UNIT: 1651		EXAMINER: Vera Afremova	
Sheet	3	of	10				

	C13	Charteris et al., "Antibiotic susceptibility of potentially probiotic Bifidobacterium isolates from the human gastrointestinal tract," Letters in Applied Microbiology, 26:333-337, (1998).	
	C14	Charteris et al., "Selective detection, enumeration and identification of potentially probiotic Lactobacillus and Bifidobacterium species in mixed bacterial populations," Int. Jour. of Food Microbiology, 35:1-27, (1997).	
	C15	Charteris, et al., "Antibiotic Susceptibility of Potentially Probiotic Lactobacillus Species," Jour. Food Protection, 61(12):1636-1643, (1998).	
	C16	Charteris, et al., "Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract," Jour. of Applied Microbiology, 84:759-768, (1998).	
	C17	Chauvière et al., "Adhesion of human Lactobacillus acidophilus strain LB to human eterocyte-like Caco-2 cells," Journal of General Microbiology, 138:1689-1696, (1992).	
	C18	Chevalier et al., "Detection of Bifidobacterium species by enzymatic methods," Jour. of Appl. Bacteriology, 68:619-624, (1990).	
	C19	Cicco et al., "Inducible Production of Interleukin-6 by Human Polymorphonuclear Neutrophils: Role of Granulocyte-Macrophage Colony-Stimulating Factor and Tumor Necrosis Factor-alpha," Blood, 75(10):2049-2052, (1990).	
	C20	Collins et al., "A Controlled Trial of Probiotic Treatment of IL-10 Knockout Mice," Gastroenterology, 116(4):1 page, (1999). Abstract G2981.	
	C21	Collins et al., "Demonstration of Probiotic Function in a Double Blind Placebo Controlled Clinical Trials in Adults," Functional Food Research in Europe, pages 40-41, (1998).	
	C22	Collins et al., "Probiotics and Man – The Host Microbe Interface," Gastroenterology, 116(4):1 page, (1999). Abstract G2982.	
	C23	Collins et al., "Selection of Probiotic Strains for Human Applications," Int. Dairy Journal, 8:487-490, (1998).	
	C24	Collins, "Probiotic Lactobacilli-Towards Defining Selection and Functional Criteria," Demonstration Fair CT96-1028, Page 27, (1996).	
	C25	Collins, "Selection of Probiotic Strains and Potential Therapeutic Applications," Book of Abstracts from Eur. Comm. Biotech and Fair Prog., page L-2, (1995).	
	C26	Collins et al., "Probiotic bacteria-interaction with the human immune system," Int. Congress and Symp. Series 219, pages 13-17, (1996).	
	C27	Collins, J.K., "Probiotics and Inflammatory Bowel Disease: Animal Models," Functional Food Research in Europe, page 124, (1998).	
	C28	Cong et al., "Genes, Bacteria, and T Cells: Ingredients for Inflammatory Bowel Disease," Gastroenterology, 115:1595-1596, (1998). (Summary by Shanahan, O'Sullivan, and Collins)	
	C29	Crabbe et al., "The Normal Microbial Flora as a Major Stimulus for Proliferation of Plasma Cells Synthesizing IgA in the Gut," Int. Arch. Allergy 34:362-375, (1968).	
	C30	Daly et al., "Biotechnology of lactic acid bacteria with special reference to bacteriophage resistance," Antonie Van Leeuwenhoek, 70:99-110, (1996).	
	C31	Darveau, Richard, "Infection, inflammation, and cancer," Nature Biotechnology, 17:19, (1999).	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/783,020		ATTY. DOCKET NO.: A0870.70000US00	
				FILING DATE: February 23, 2004		CONFIRMATION NO.: 3753	
				APPLICANT: Collins et al.			
				GROUP ART UNIT: 1651		EXAMINER: Vera Afremova	
Sheet	4	of	10				

	C32	Dawson et al., "18 pH, buffers, and physiological media," Data For Biochemical Research, pages 417-448, (1969).	
	C33	Dekker et al., "Sensitive Pulsed Amperometric Detection of Free and Conjugated Bile Acids in Combination with Gradient Reversed-Phase HPLC," Chromatographia, 31(11/12):549-553, (1991).	
	C34	Dinarello et al., "New Concepts on the Pathogenesis of Fever," Reviews of Infectious Diseases, 10(1):168-189, (1988).	
	C35	Donnelly, et al., "Differential Regulation of IL-1 Production in Human Monocytes by IFN-γ and IL-4," Journal of Immunology, 145(2):569-575, (1990).	
	C36	Dunne et al., "Epithelial Adhesion of Probiotic Microorganisms in vitro and in vivo," Gastroenterology, 116(4):1 page, (1999). Abstract G3058.	
	C37	Dunne et al., "Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials," Antonie Van Leeuwenhoek, XP000929178, 76:279-292, (1999).	
	C38	Favier et al., "Fecal β-D-Galactosidase Production and Bifidobacteria Are Decreased in Crohn's Disease," Digestive Diseases and Sci., 42(4):817-822, (1997).	
	C39	Feency et al., "Lack of Specific Systemic Immune Response on Oral Consumption of Probiotic Lactobacilli," Int. Dairy Journal, 8(5/6):1 page, (1998).	
	C40	Ferrante et al., "Effects of Tumour Necrosis Factor Alpha and Interleukin-1 Alpha and Beta on Human Neutrophil Migration, Respiratory Burst and Degranulation," Int. Archs Allergy Appl. Immun., 86:82-91, (1988).	
	C41	Flynn et al., "Isolation and Characterisation of the Novel Antibacterial Proteins, ABP-1 and ABP-118 from Human Isolates Lactobacillus salivarius subsp. salivarius UCC-1 and UCC-118," Intl. Dairy Jour., 8(5/6):1 page, (1998).	
	C42	Fuller, "Probiotics in man and animals," Jour. of Applied Bacteriology, 66:365-378, (1989).	
	C43	Gahan et al., "Innate resistance to Listeria monocytogenes in tumor-bearing mice," Jour. of Leukocyte Biology, 62:726-732, (1997).	
	C44	Ganguly et al., "Mechanism of action of cholera toxin & other toxins," Indian J. Med. Res., 104:28-37, (1996).	
	C45	Gardiner et al., "Characterisation of Cheddar Cheese Harboring Probiotic Lactobacillus Adjuncts," Int. Dairy Journal, 8(5/6):597, (1998).	
	C46	Gardiner et al., "Cheddar Cheese as a Probiotic Delivery System," Sixth Symposium on Lactic Acid Bacteria, Abstract J28, (1999).	
	C47	Gardiner et al., "Evaluation of Cheddar Cheese as a Food Carrier for Delivery of a Probiotic Strain to the Gastrointestinal Tract," J. Dairy Sci., 82:1379-1387, (1999).	
	C48	Gardiner et al., "Influence of a Probiotic Adjunct Culture of Enterococcus faecium on the Quality of Cheddar Cheese," J. Agric. Food Chem., 47:4907-4916, (1999).	
	C49	Gardiner et al., "Preparation of Spray Dried Powders Harboring High Levels of Probiotic Lactobacilli," Sixth Symp. on Lactic Acid Bacteria, Abstract J29, (1999).	
	C50	Gardiner, et al., "Development of a Probiotic Cheddar Cheese Containing Human-Derived Lactobacillus paracasei Strains," Applied and Env. Microbiology, pages 2192-2199, (1998).	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/783,020		ATTY. DOCKET NO.: A0870.70000US00	
				FILING DATE: February 23, 2004		CONFIRMATION NO.: 3753	
				APPLICANT: Collins et al.			
				GROUP ART UNIT: 1651		EXAMINER: Vera Afremova	
Sheet	5	of	10				

	C51	Gatanaga et al., "Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients," Proc. Natl. Acad. Sci, 87:8781-8784, (1990).	
	C52	Gibson, Glenn, "Dietary modulation of the human gut microflora using prebiotics," Jour. of Nutrition, 80(2):S209-S212, (1998).	
	C53	Gilliland, Stanley, "Health and nutritional benefits from lactic acid bacteria," FEMS Microbiology Reviews, 87:175-188, (1990).	
	C54	Gionchetti et al., "Microflora in the IBD Pathogenesis: Possible Therapeutic Use of Probiotics" Gastroenterology Intl., 11(1):108-110, (1998).	
	C55	Groot, J.A., "Correlation between electrophysiological phenomena and transport of macromolecules in intestinal epithelium," The Veterinary Quarterly, 20(3):S45-S49, (1998).	
	C56	Halpern et al., "Treatment of Irritable Bowel Syndrome with Lactol Fort: A Randomized, Double-Blind, Cross-Over Trial," Am Jour. of Gastroenterology, 91(8):1579-1585, (1996).	
	C57	Henderson et al., "Cytokines, homeostasis, networks and disease," Bacteria-Cytokine Interactions in Health and Disease, pages 79-130, (1998).	
	C58	Houde et al., "Treatment of Acute Enteritis with Oral Administration of Short-Term High-Dose Bifidobacteria," Chinese Jour of Microecology, 6(6):47, (1994).	Y
	C59	Huis et al., "Establishing a scientific basis for probiotic R&D," 12:6-8, (1994).	
	C60	Inagaki et al., "Causes of Death in Cancer Patients," Cancer, 33(2):568-573, (1974).	
	C61	Isolauri et al., "Oral Bacteriotherapy for Viral Gastroenteritis," Digestive Diseases and Sciences, 39(12):2595-2600, (1994).	
	C62	Jinggang, Lan, "Immunopotentiating Activity of Bifidobacterium and Its Significance," For. Med. Sci., Clinic Biochem & Med Test, 19(5):231-233, (1998).	Y
	C63	Jong, S.C., "Probiotics for Humans and Animals," ATCC Quarterly Newsletter, 13(1):1-4, (1993).	
	C64	Kagnoff, "Immunology of the Intestinal Tract," Gastroenterology, 105:1275-1280, (1993).	
	C65	Kato et al., "Suppressive Effects of the Oral Administration of Lactobacillus Casei on Type II Collagen-Induced Arthritis in DBA/1 Mice," Life Sciences, 63(8):635-644, (1998).	
	C66	Kawakami et al., "A Group of Bactericidal Factors Conserved by Vertebrates For More Than 300 Million Years," Journal of Immunology, 132(5):2578-2581, (1984).	
	C67	Kim et al., "The Properties of Bifidobacteria Isolated from Korean," Korean Journal of Dairy Science, 20(3):191-204, (1998).	Y-Abstract
	C68	Kim, Hyung, "Characterization of Lactobacilli and Bifidobacteria as applied to Dietary Adjuncts ¹ ," Cultured Dairy Products Journal, pages 6-9, (1988).	
	C69	Klaenhammer, Todd, "Genetics of bacteriocins produced by lactic acid bacteria," FEMS Microbiology Rev., 12:39-86, (1993).	
	C70	Kühn, et al., "Interleukin-10-Deficient Mice Develop Chronic Enterocolitis," Cell, 75:263-274, (1993).	
	C71	Kulkarni et al., "Inhibitory Effect of Bifidobacterium longum Cultures on the Azoxymethane-Induced Aberrant Crypt Foci Formation and Fecal Bacterial β -Glucuronidase," Proc. Soc. Experim. Biol. Med., 207:278-283, (1994).	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/783,020		ATTY. DOCKET NO.: A0870.70000US00	
				FILING DATE: February 23, 2004		CONFIRMATION NO.: 3753	
				APPLICANT: Collins et al.			
				GROUP ART UNIT: 1651		EXAMINER: Vera Afremova	
Sheet	6	of	10				

	C72	Lamm et al., "Interaction of antigens and antibodies at mucosal surfaces," Ann Rev Microbiol, 51:311-40, (1997). (Previously cited as Ramos et al.)	
	C73	Lee et al., "The coming of age of probiotics," Trends in Food Science & Technology, 6:241-245, (1995).	
	C74	Legrand-Defretin et al., "Ion-Pair High-Performance Liquid Chromatography of Bile Salt Conjugates: Application to Pig Bile," LIPIDS, 26(8):578-583, (1991).	
	C75	Leonard, et al., "Regulation of the Inflammatory Response in Animal Models of Multiple Sclerosis by Interleukin-12," Critical Reviews in Immunology, 17:545-553, (1997).	
	C76	Lucey et al., "Developing Fields in Food Biotechnology," Food Science and Technology, 11(4):230-233, (1997).	
	C77	Madsen et al., " <i>Lactobacillus SP</i> prevents development of enterocolitis in interleukin-10 gene deficient mice," Gastroenterology, 112(4):1030, (1997).	
	C78	Malefyt et al., "Interleukin 10 (IL-10) and Viral IL-10 Strongly Reduce Antigen-specific Human T Cell Proliferation by Diminishing the Antigen-presenting Capacity of Monocytes via Downregulation of Class II Major Histocompatibility Complex Expression," J. Exp. Med., 174:915-924, (1991).	
	C79	Mangan et al., "Lipopolysaccharide, Tumor Necrosis Factor- α , and IL-1 β Prevent Programmed Cell Death (Apoptosis) in Human Peripheral Blood Monocytes," Journal of Immunology, 146(5):1541-1546, (1991).	
	C80	Marteau et al., "Potential of using lactic acid bacteria for therapy and immunomodulation in man," FEMS Microbiology Reviews, 12:207-220, (1993).	
	C81	Mattila-Sandholm, "Novel Methods for Probiotic Research," Demonstration Project Fair2 CT96-1028, Pages 11-15, (1997).	
	C82	Mattila-Sandholm, et al., "Probiotics: towards demonstrating efficacy," Trends in Food Sci & Tech., 10:393-399, (1999).	
	C83	McBrearty et al., "Probiotic Bifidobacteria and Their Identification Using Molecular Genetic Techniques," Proc. of British Nutritional Foundation, pages 97-107, (2000).	
	C84	McCracken, et al., "Probiotics and the Immune System," Probiotics a Critical Review, pages 85-113, (1999).	
	C85	McFarland, et al., "Pharmaceutical Probiotics for the Treatment of Anaerobic and Other Infections," Anaerobe, 3:73-78 (1997).	
	C86	McGee et al., "A synergistic relationship between TNF- α , IL-1 β , and TGF- β 1 on IL-6 secretion by the IEC-6 intestinal epithelial cell line," Immunology, 86:6-11, (1995).	
	C87	Medaglini et al., "Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium <i>Streptococcus gordonii</i> after oral colonization," Proc. Natl. Acad. Sci, 92:6868-6872, (1995).	
	C88	Mestan et al., "Antiviral effects of recombinant tumour necrosis factor <i>in vitro</i> ." Nature. 323:816-819, (1986). (Previously cited as Wong et al.)	
	C89	Morrissey et al., "Election of a Probiotic Strain to Modify Human Gut Flora and a Controlled Trial of Delivery and Efficacy," Ir. Soc. of Gastroenterology, 167(8):7, (1998).	
	C90	Murphy et al., "Evaluation and Characterisation of Probiotic Therapy in the CD45RB ^{HI} Transfer Model of Colitis," Gastroenterology, 116(4):A780, (1999). Abstract 3382.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/783,020		ATTY. DOCKET NO.: A0870.70000US00	
				FILING DATE: February 23, 2004		CONFIRMATION NO.: 3753	
				APPLICANT: Collins et al.			
				GROUP ART UNIT: 1651		EXAMINER: Vera Afremova	
Sheet	7	of	10				

	C91	Murphy et al., "Long-term Colonisation with Lactobacillus salivarius subsp. salivarius UCC118: A Probiotic Candidate," Intl. Dairy Journal, 8(5/6):3 pages, (1998).	
	C92	Murphy, et al., "In vivo assessment of potential probiotic Lactobacillus salivarius strains: evaluation of their establishment, persistence, and localisation in the murine gastrointestinal tract." Microbiol. Ecology in Health and Disease, pages 149-157, (1999).	
	C93	Neutra et al., "M Cells as a Pathway for Antigen Uptake and Processing," Essentials of Mucosal Immunology, 196:29-35, (1996).	
	C94	O'Halloran et al., "Adhesion of Potential Bacteria to Human Epithelial Cell Lines," Intl. Dairy Jour., 8(5/6):3 pages, (1998).	
	C95	Oksanen et al., "Prevention of Travellers' Diarrhoea by Lactobacillus GG," Annual Med., 22(1):53-56, (1990).	
	C96	O'Mahony et al., "Probiotic Bacteria and Pathogenic Bacteria Elicit Differential Cytokine Responses From Dendritic Cells," XP001097379, (2001). Abstract 1625.	
	C97	O'Mahony et al., "Probiotic Bacteria and the Human Immune System," Sixth Symp. on Lactic Acid Bacteria, pages 63-70, (1999).	
	C98	O'Mahony, et al., "Consumption of Probiotic Bacteria Ameliorates Enterocolitis in IL-10 Knock Out Mice," Irish Jour. Med. Sci., 168(5):9, (1999).	
	C99	O'Mahony, et al., "UCC118 Modulates Proinflammatory Cytokine Production In Vitro," Ir. J. Med. Sci., 168(9), (1999).	
	C100	O'Mahony et al., "Probiotic Treatment of Enterocolitis in IL-10 Knock Out Mice." Sixth Symp on Lactic Acid Bacteria. 2 pages. Sept 19/23, (1999). Abstract J30.	
	C101	O'Riordan, et al., "Assessment of Bifidobacterium Strains for Antimicrobial and Exopolysaccharide Production and Evaluation of Pulsed-field Gel Electrophoresis as a Method for Identifying or Discriminating between Bifidobacterial Strains," Intl. Dairy Jour., 8(5/6): 3 pages (1998).	
	C102	O'Riordan et al., "Determination of genetic diversity within the genus Bifidobacterium and estimation of chromosomal size," FEMS Microbiology Letters, 156:259-264, (1997).	
	C103	O'Riordan et al., "Evaluation of bifidobacteria for the production of antimicrobial compounds and assessment of performance in cottage cheese at refrigeration temperature," Journal of Applied Microbiology, 85:103-114, (1998).	
	C104	O'Sullivan et al., "Isolation and Selection of Normal Gut Microflora for Use as Prophylactic Probiotic Agents," Irish Society of Gastroenterology, Proc. in Dublin, June 7-8, 1991, pages 419-420.	
	C105	O'Sullivan et al., "Probiotic Bacteria in the Human Gastro Intestinal Tract (Myth or Reality)," Irish Jour of Med Sci, Proc. of the Irish Soc. of Gastroenterology, Dec. 4-5, 1992, page 273.	
	C106	O'Sullivan et al., "Probiotic bacteria: myth or reality?," Trends in Food Science & Technology, 3:309-314, (1992).	
	C107	O'Sullivan et al., "The Human Gut as a Source of Probiotic Bacteria - Myth or Reality?" Irish Jour. of Med. Sci., page 25, (1993).	
	C108	Panwala, et al., "A Novel Model of Inflammatory Bowel Disease: Mice Deficient for the Multiple Drug Resistance Gene, mdr1a, Spontaneously Develop Colitis," Jour. of Immunology, 161:5733-5744, (1998).	
	C109	Present et al., "Infliximab for the treatment of fistulas in patients with Crohn's Disease," New Eng. Jour. of Med., 340(18):1398-1405, (1999).	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/783,020		ATTY. DOCKET NO.: A0870.70000US00	
				FILING DATE: February 23, 2004		CONFIRMATION NO.: 3753	
				APPLICANT: Collins et al.			
				GROUP ART UNIT: 1651		EXAMINER: Vera Afremova	
Sheet	8	of	10				

	C110	Raychaudhuri et al., "Fully mobilizing host defense: Building better vaccines," Nat. Biotechnol., 16:1025-1031, (1998).	
	C111	Reddy, Bandaru, "Possible Mechanisms by Which Pro- and Prebiotics Influence Colon Carcinogenesis and Tumor Growth ¹ ," Amer. Soc. for Nut. Sci., pages 1478S-1482S, (1999).	
	C112	Rowland, Ian, "Toxicology of the Colon: Role of the Intestinal Microflora," Human Colonic Bacteria, pages 155-174, (1995).	
	C113	Rumney et al., "Effects of risk-associated human dietary macrocomponents on processes related to carcinogenesis in human-flora-associated (HFA) rats," Carcinogenesis, 14(1):79-84, (1993).	
	C114	Saito et al., "Effects of Soybean Oligosaccharides on the Human Gut Microflora in In vitro Culture," Microbial Ecology in Health & Disease, 5:105-110, (1992).	
	C115	Salminen et al., "Demonstration of safety of probiotics - a review," Int. Jour. of Food Microbiology, 44:93-106, (1998).	
	C116	Sarath et al., "Protease assay methods," Proteolytic Enzymes, Chapter 3, pages 25-55, (1989). (Previously cited as Gauthan et al.)	
	C117	Sarem-Damerdjii et al., "In vitro colonization ability of human colon mucosa by exogenous Lactobacillus strains," FEMS Microbiology Letters, 131:133-137, (1995).	
	C118	Savage, D. "Interactions Between the Host and its Microbes," Microbial Ecology of the Gut, pages 277-310, (1977).	
	C119	Scardovi et al., "Genus Bifidobacterium," Bergey's Manual of Systemic Bacteriology," 2:1418-1434, (1986).	
	C120	Schmitt et al., "The Immunostimulatory Function of IL-12 in T-Helper Cell Development and Its Regulation by TGF- β , IFN- γ and IL-4," Chem. Immunology, 68:70-85, (1997).	
	C121	Shanahan et al., "Immunosuppressive agents in inflammatory bowel disease: Current status and future prospects," Can J Gastroenterol, 8(6):383-387, (1994).	
	C122	Shanahan, "Pathogenic mechanisms in inflammatory bowel disease," Gastrointestinal Function, 13:13-28, (1995).	
	C123	Shanahan et al., "Grand Entry for Listeria," Gastroenterology, 112:1045-1046, (1997).	
	C124	Shanahan, et al., "In vivo Primed Cytotoxic T Cells in Inflammatory Bowel Disease," Inflammatory Bowel Disease, Int'l Congress, pages 101-106, (1988).	
	C125	Shanahan, Fergus, "The Intestinal Immune System," Physiology of the Gastrointestinal Tract, pages 643-684, (1994).	
	C126	Shanahan et al., "Immunosuppressive agents in IBD: current status and future prospects." Inflammatory Bowel Disease, pages 367-373, (1994).	
	C127	Siitonen et al., "Effect of Lactobacillus GG Yoghurt in Prevention of Antibiotic Associated Diarrhoea," Annual Med., 22(1):57-59, (1990).	
	C128	Singh et al., "Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis," Carcinogenesis, 18(4):833-841, (1997).	
	C129	Stallmach et al., "Induction and modulation of gastrointestinal inflammation," Trends Immunology Today, 19(10):438-441, (1998).	
	C130	Stanton et al., "Probiotic Cheese," Int. Dairy Journal, 8:491-496, (1998).	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/783,020		ATTY. DOCKET NO.: A0870.70000US00	
				FILING DATE: February 23, 2004		CONFIRMATION NO.: 3753	
				APPLICANT: Collins et al.			
				GROUP ART UNIT: 1651		EXAMINER: Vera Afremova	
Sheet	9	of	10				

	C131	Steidler et al., "Mucosal Delivery of Murine Interleukin-2 (IL-2) and IL-6 by Recombinant Strains of Lactococcus lactis Coexpressing Antigen and Cytokine," Infection and Immunity, 66(7):3183-3189, (1998).	
	C132	Tagg et al., "Bacteriocins of Gram-Positive Bacteria," Bacteriological Reviews, 40(3):722-756, (1976).	
	C133	Takiguchi et al., "Effects of Fermented-Milk Administration on Fecal Microflora and Putrefactive Metabolites of Healthy Adults and Healthy Elderly Persons," BIFIDUS-FLORES, FRUCTUS ET SEMINA 9, pages 135-140, (1996).	Y-Abstract
	C134	Tancrede, C., "Role of Human Microflora in Health and Disease," Eur. J. Clin. Microbiol. Infect. Dis., 11(11):1012-1015, (1992).	
	C135	Tannock, Gerald, "Effect of Dietary and Environmental Stress on the Gastrointestinal Microbiota," Human Intestinal Microflora in Health & Disease, pages 517-539, (1983).	
	C136	Thornton et al., "Bile tolerance and bile salt hydrolase activity of lactobacilli and bifidobacteria isolated from the human intestine," Gastroenterology, 108(4):A928, (1995).	
	C137	Thornton et al., "Human Intestinal Probiotic Bacteria: Production of Antimicrobial Factors," Irish Jour of Med. Sci., 2 pages, (1993).	
	C138	Thornton et al., "Towards an Understanding of the Survival Mechanisms Employed by the Health Promoting Commensal Flora of the Human Small Intestine," Irish Jour. of Med. Sci., Page 603, (1994).	
	C139	Thornton et al., "Determination of stringent criteria essential to the survival/growth/colonisation of probiotic human intestinal tract bacteria," Book of Abstracts Eur. Comm. Biotech and Fair Programmes, page 28, (1995). (Previously cited as Collins et al.)	
	C140	Thornton et al., "The Production of a Novel Antimicrobial Substance by Human Intestinal Microflora," Irish Jour. of Med Sci, pages 603-604, (1994).	
	C141	Thornton, et al., "Bile Acid Tolerance and Deconjugating Activity of Lactobility," Irish Jour. of Med. Sci., 2 pages, (1994).	
	C142	Toba et al., "Potential of Lactobacillus gasseri isolated from infant faeces to produce bacteriocin," Letters in Applied Microbiology, 12:228-231, (1991).	
	C143	van Eys, Jan, "Nutrition and Neoplasia," Nutrition Reviews, 40(12):353-359, (1982).	
	C144	Vaughan et al., "Identification and characterization of helveticin V-1829, a bacteriocin produced by Lactobacillus helveticus 1829," Journal of Applied Bacteriology, 73:299-308, (1992).	
	C145	Vaughan et al., "Isolation from food sources, of lactic acid bacteria that produced antimicrobials," Journal of Applied Bacteriology, 76:118-123, (1994).	
	C146	Veld et al., "Selection criteria for probiotic micro-organisms," International Congress and Symposium Series 219, pages 27-36 (1996).	
	C147	Wahl et al., "IFN- γ Inhibits Inflammatory Cell Recruitment and the Evolution of Bacterial Cell Wall-Induced Arthritis," Journal of Immunology, 146(1):95-100, (1991).	
	C148	Walker, Richard, "New strategies for using mucosal vaccination to achieve more effective immunization," Vaccine, 12:387-400, (1994).	
	C149	Wu, et al., "Transfection of Ovarian Cancer Cells with Tumor Necrosis Factor- α (TNF- α) Antisense mRNA Abolishes the Proliferative Response to Interleukin-1 (IL-1) but Not TNF- α ," Gynecologic Oncology, 53:59-63, (1994). (Formerly cited as Meeker et al.)	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/783,020	ATTY. DOCKET NO.: A0870.70000US00
				FILING DATE: February 23, 2004	CONFIRMATION NO.: 3753
				APPLICANT: Collins et al.	
				GROUP ART UNIT: 1651	EXAMINER: Vera Afremova
Sheet	10	of	10		

	C150	Yang et al., "Genetics of Inflammatory Bowel Disease," Chapter 3, pages 32-64, (1994).	
	C151	Cong et al., "CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease," J Exp Med, 187(6):855-64, (1998).	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.